Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 14, 2004 - Issue 1
Submit an article Journal homepage
60
Views
31
CrossRef citations to date
0
Altmetric
Review

Protein tyrosine kinase inhibitors as anticancer agents

Claudiu T Supuran Università degli Studi di Firenze, Laboratorio di Chimica Bioinorganica, Rm. 188, Via della Lastruccia 3, I-50019 Sesto Fiorentino (Firenze), Italy. [email protected]
&
Andrea Scozzafava Università degli Studi di Firenze, Laboratorio di Chimica Bioinorganica, Rm. 188, Via della Lastruccia 3, I-50019 Sesto Fiorentino (Firenze), Italy. [email protected]
Pages 35-53 | Published online: 02 Mar 2005

Bibliography

  • SUN L, MCMAHON G: Inhibition of tumor angiogenesis by synthetic receptor tyrosine kinase inhibitors. Drug Dev. Today (2000) 5:344–353.
  • FABBRO D, PARKINSON D, MATTER A: Protein tyrosine kinase inhibitors: new treatment modalities ? Curr. Opin. Phannacoi (2002) 2:374–381.
  • ••Excellent review on the development ofimatinib.
  • LEVITZKI A: Tyrosine kinases as targets for cancer therapy. Eur. Cancer. (2002) 38 (Supp1.5):S11–S18.
  • LEE AV, SCHIFF R, CUI X et al.: New mechanisms of signal transduction inhibitor action: receptor tyrosine kinase down-regulation and blockade of signal transactivation. Clin. Cancer Res. (2003) 9:516S–523S.
  • RITTER CA, ARTEAGA CL: The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. Semin. Oncol. (2003) 30\(Supp1.1):3–11.
  • •Good review on EGFR TK inhibitors.
  • CROOM KF, PERRY CM: Imatinib mesylate: in the treatment of gastrointestinal stromal tumours. Drugs (2003) 63:513–522.
  • DREVS J, MEDINGER M, SCHMIDT-GERSBACH C, WEBER R, UNGER C: Receptor tyrosine kinases: the main targets for new anticancer therapy. Curr. Drug Targets (2003) 4:113–121.
  • MANLEY PW, COWAN-JACOB SW, BUCHDUNGER E et al.: Imatinib: a selective tyrosine kinase inhibitor. Eur. Cancer (2002) 38 (Supp1.5):S19–S27.
  • HUBBARD SR: Protein tyrosine kinases: autoregulation and small-molecule inhibition. Curt: Opin. Struct. Biol. (2002) 12:735–741.
  • SATTLER M, PRIDE YB, MA P et al.:A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res. (2003) 63:5462–5469.
  • GEORGE D: Targeting PDGF receptors incancer-rationales and proof of concept clinical trials. Adv. Exp. Med. Biol. (2003) 532:141–151.
  • SATTLER M, SCHEIJEN B, WEISBERG E, GRIFFIN JD: Mutated tyrosine kinases as therapeutic targets in myeloid leukemias. Adv. Exp. Med. Biol. (2003) 532:121–140.
  • DRUKER BJ, TALPAZ M, RESTA DJ et al.: Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia. N Engl. I Med. (2001) 344:1031–1037.
  • TALPAZ M, SILVER RT, DRUKER BJ et al.: Gleevec induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a Phase II study. Blood (2002) 99:1928–1937.
  • THIESING JT, OHNO-JONES S, KOLIBABA KS, DRUKER BJ: Efficacy of STI-571, an ABL tyrosine kinase inhibitor, in conjunction with other antileukemic agents against Bcr-Abl-positive cells. Blood (2000) 96:3195–3199.
  • BONOMI P: Clinical studies with non-Iressa EGFR tyrosine kinase inhibitors. Lung Cancer (2003) 41\(Supp1.1):S43–S48.
  • SCHUENEMAN AJ, HIMMELFARB E, GENG L et al.: SU-11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res. (2003) 63:4009–4016.
  • WAKELING AE: Epidermal growth factor receptor tyrosine kinase inhibitors. Curl: Opin. Pharmacol (2002) 2:382–387.
  • •Up-to-date and interesting review.
  • BONOMI P: Erlotinib: a new therapeutic approach for non-small cell lung cancer. Expert Opin. Investig. Drugs. (2003) 12:1395–1401.
  • WANG Y, METCALF CA, SHAKESPEARE WC et al.: Bone-targeted 2,6,9-trisubstituted purines: novel inhibitors of Src tyrosine kinase for the treatment of bone diseases. Bioorg. Med. Chem. Lett. (2003) 13:3067–3070.
  • RACHID Z, BRAHIMI F, KATSOULAS A, TEOH N, JEAN-CLAUDE BJ: The combi-targeting concept: chemical dissection of the dual targeting properties of a series of `combi-triazenes'. Med. Chem. (2003) 46:4313–4321.
  • CIARDIELLO F, CAPUTO R, BIANCO R et al.: Inhibition of growth factor production and angiogenesis in human cancer cells by ZD-1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin. Cancer. Res. (2001) 7: 14 5 9–1 46 5 .
  • RANSON M, HAMMOND LA, FERRY D et al.: ZD-1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a Phase I trial.' Clin. Oncol (2002) 20:2240–2250.
  • DREVS J, SCHMIDT-GERSBACH C, MROSS K et al.: Surrogate markers for the assessment of biological activity of the VEGF-receptor inhibitor PTK-787/ ZK-222584 (PTK/ZK) in two clinical Phase I trials. Proc. ASCO (2002) 85a:Abstract 337.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.